Effect of Vitamin C to The Plasma Level of Interleukin-6, Plasma MDA and Length of Hospitalization of COPD Exacerbation Patient
DOI:
https://doi.org/10.36497/jri.v38i1.136Keywords:
vitamin C, acute exacerbation of COPD, plasma IL-6, plasma MDA, length of hospitalizationAbstract
Background: Exacerbation is an acute condition characterized by worsening of symptoms that require a change in therapy. Increased inflammation of the airways and lungs during exacerbations causes an increase in plasma IL-6 and MDA levels and causes most patients needed treatment at the hospital. Vitamin C is an antioxidant vitamin that has anti-inflammatory and antioxidant effects so that it can be added to COPD exacerbations therapy. This study aims to determine the effect of vitamin C on plasma IL-6, plasma MDA levels and length of hospitalization of acute exacerbation of COPD patients. Methods: This research is an experimental study with pre-test and post-test design. Subjects consisted of 33 patients with exacerbation of COPD were treated at the Soehadi Pridjonegoro Hospital Sragen in October-November 2015 which were selected by purposive sampling. Subjects were divided into two groups, the treatment group (n=16) received vitamin C therapy 1x1000 mg/day and the control group (n=17) received 5 mL of NaCl 0.9%. Levels of IL-6 plasma and plasma MDA was measured on admission and at discharge criteria are met. Length of hospitalization is calculated based on the number of days’ patients in hospital. Results: There was no statistically significant difference to decreased of IL-6 plasma level (P=0.379), MDA plasma level (P=0.27) and length of hospitalization (P=0.24) between treatment and control group. Conclucions: The addition of vitamin C 1x1000 mg/day during hospitalization is not helpful to decreased in levels of plasma IL-6, plasma MDA and length of hospitalization in this study. (J Respir Indo 2018; 38(1): 24-32)Downloads
References
Global initiative for chronic obstructive lung disease. 2014. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease update 2015.. [Cited 2016 January 5th]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf
Evensen AE. Management of COPD Exacerbations. [Cited 2016 februari 10th]. Available from: ww w.aafp.org/afp.
Suradi. Peran kadal IL-1β, IL-12, IFN-γ dan IL-10 terhadap kadar elastase MMP-9 pada emfisema paru. [Disertasi] Surabaya: Universitas Airlangga, 2004.
Mackay AJ, Donaldson GC, Patel ARC, Jones PW, Hurst JR. Usefulness of chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbation. Am J Crit Care Med. 2012;185:1218-24.
Cavalcante AG, Brain PF. The role of oxidative stress in COPD: current concepts and perspectives. J Bras Pneumol. 2009;35:1227-37.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.
Kubera J, Hammerman K, Williams CMM, Hubeau C. Interleukin-6 neutralization alleviates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation. J Inflamm (Lond). 2013;10:P33.
Roca M, Verduri A, Corbetta L, Clini B, Fabbri LM, Beghe B. Mechanism of acute exacerbations of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest. 2013;43:510-21.
Antuz B, Harnasi G, Drozdovszky O, Barta I. Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde. Respirology. 2013;19:74-9.
Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543-59.
Desai U, Gothi D, Joshi JM. COPD exacerbation: clinical management options. Indian Journal of Clinical Medicine. 2012;3:1-15.
Adikwu E, Deo O. Hepatoprotective effect of vitamin C (ascorbic acid). Pharmacology & Pharmacy. 2013;4:84-92.
Anitra CC, Margreet C M. Synthetic or food derived vitamin C are they equally bioavailable? Nutrients. 2013;5:4284-304.
Carcamo JM, Pedraza A, Ojeda OB, Zhang B, Sanchez R, Golde DW. Vitamin C is kinase inhibitor: dehydroascorbic acid anhibits IKβα kinase β. Mol Cell Biol. 2004;8:6645-52.
Vijayan VK. Chronic obstructive pulmonary disease. Indian Journal of Medical Research. 2013;137:251-69.
Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease. Am Thorac Soc. 2007;4:512-21.
Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281-90.
Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bllello JA, Hagan GW, et al. Use plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-74.
Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:1-10.
Mikirova N, Rogera A, Casciari J, Taylor P. Effect of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis. Modern Research in Inflammation. 2012;1:26-32.
Moraes MR, Costa AC, Correx KS, Kipnis APJ, Rabahi MF. Interleukin-6 and interleukin-8 blood level’s poor association with the severity and clinical profile of ex-smokers with COPD. Int J Chron Obstruct Pulmon Dis. 2014;4:735-43.
Ge M, O’Reilly A, Baillie N, Twentyman G, Sturt J, Fitzpatrick M, et al. Vitamin C: evidence, application and commentary. New Zeal Fam Physician. 2008;35:312-8.
Downloads
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
